Dupilumab normalizes the eosinophilic esophagitis disease transcriptome
Authors:
Open Access
- 22 April 2026
- journal article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 158 (2) , 542-554
Abstract
No abstract availableKeywords
Funding Information
- Sanofi
- Regeneron Pharmaceuticals
This publication has 44 references indexed in Scilit:
- Dupilumab Normalized The Expression Of Genes Dysregulated In Eosinophilic Esophagitis (EoE) In Esophageal Biopsies From A Clinical Trial Of Children Aged 1–11 YearsJournal of Allergy and Clinical Immunology, 2024
- Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Gastroenterology & Hepatology, 2023
- Single-cell RNA sequencing of mast cells in eosinophilic esophagitis reveals heterogeneity, local proliferation, and activation that persists in remissionJournal of Allergy and Clinical Immunology, 2022
- IL-4 expressing cells are recruited to nerve after injury and promote regenerationExperimental Neurology, 2021
- Clinical relevance of esophageal subepithelial activity in eosinophilic esophagitisJournal of Gastroenterology, 2019
- Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitisJournal of Allergy and Clinical Immunology, 2019
- Elevated Tryptase in EoE Is an Independent Phenomenon Associated with Extra-Esophageal SymptomsDigestive Diseases and Sciences, 2018
- Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitisJournal of Allergy and Clinical Immunology, 2014
- Histopathologic Features of Eosinophilic Esophagitis and Eosinophilic Gastrointestinal DiseasesGastroenterology Clinics of North America, 2014
- Involvement of mast cells in eosinophilic esophagitisJournal of Allergy and Clinical Immunology, 2010